Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LHT344
- Development stage
- Phase 1
- Lead developer
- Novartis
- Administration
- Oral
01
Overview
LHT344 is an investigational drug that has undergone early-phase clinical evaluation to assess its safety and pharmacokinetics in healthy subjects. The available information indicates that it was studied in a single-center, open-label trial involving both single and multiple oral doses administered to Chinese healthy volunteers[1][2]. No additional details regarding its mechanism of action, therapeutic class, or primary indication are provided in the available sources.
Beyond the preview
Go deeper on LHT344.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LHT344.